April 25 is International DNA Day, and it marks the completion of a decade-long project to sequence the DNA of Hong Kong's ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

A further case study is the activation of the class B1 GPCR glucagon-like peptide-1 receptor (GLP-1R ... To our knowledge, this is the first time the whole sequence of events leading from an inactive ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in ...

“GLP-1 receptor antagonists and SGLT-2 inhibitors have been demonstrated to control the sugar, and also reduce the inflammation (a key driver of Alzheimer’s disease) and reduce vascular risk ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also ...